Globrands Group 2025: Cash Flow Recovered, but 2027 Is Already in the Room

Understanding the Company

At first glance, Globrands looks like a broad consumer-goods distributor. That is only partly true. This is first and foremost a tobacco distribution engine, with two smaller legs in sweets and snacks and in lifestyle products. The real economics still sit mostly in one place: distributing JTI and BAT products. That matters because 2025 showed both what is working and what is still unresolved. What is working is the ability to hold market share, pass through pricing, and bring operating cash flow back to a healthier level. What remains unresolved is the combination of supplier dependence, heavy working-capital needs, and short-term credit that still plays a central role in the funding structure.

The first screen for 2025 does not look bad. Sales rose to NIS 3.70 billion, net revenue rose to NIS 784.9 million, gross profit increased to NIS 237.7 million, and cash flow from operations jumped to NIS 59.5 million from NIS 26.2 million in 2024. The lifestyle-products segment also grew sharply thanks to underlying activity and the consolidation of Calir. But anyone stopping there misses the core story. Operating profit fell to NIS 85.6 million, net profit fell to NIS 52.7 million, and the fourth quarter was the weakest quarter of the year, with net profit of only NIS 6.8 million.

This is the active bottleneck today: the business generates cash, but it still does not create comfortable balance-sheet flexibility. At the end of 2025, the company had current assets of NIS 544.3 million against current liabilities of NIS 526.1 million, bank credit of NIS 357.3 million, cash of only NIS 12.2 million, and a tangible-equity-to-balance-sheet ratio of 8.5%. That is covenant compliance, but it is not the kind of compliance that lets investors ignore funding risk.

That is also why 2027 is already in the room. The company disclosed that it is negotiating with JTI over the renewal of the distribution agreement that expires in February 2027, and that if a new agreement is signed, the profit rate on JTI sales is expected to decline versus 2024 and 2025. When JTI alone accounts for 46.2% of net sales and BAT adds another 29.4%, the Globrands story is not just about how 2025 looked. It is mainly about whether 2026 can hold together, and what 2027 will look like.

The 2025 economic map looks like this:

Events and Triggers

The JTI negotiation is the real trigger

First trigger: on February 2, 2026, the company said it was negotiating with JTI over the renewal of the agreement that expires in February 2027. This is not a footnote. The company states explicitly that JTI is also negotiating with other parties interested in distributing its products in Israel, and that if a new agreement is signed, the annual profit rate from JTI sales is expected to decline from 2027 versus 2024 and 2025. The company also says it cannot yet estimate the size of that decline. That wording forces a step back: the market does not need to wait for February 2027. It will start reading 2026 through the lens of the renewal economics.

The weight of this issue is obvious. JTI accounted for 46.2% of 2025 net sales, BAT for 29.4%, and together the two suppliers represented 75.6% of the group’s net sales. So even if 2025 looks stable, the business is still not diversified in the way equity holders would want it to be.

Calir broadens the mix, but does not yet change the identity of the business

Second trigger: Calir was acquired in July 2025 through G.B. Pharma. The transaction included NIS 32 million in cash, contingent consideration measured at NIS 5.5 million at year-end, and first-time consolidation from July 1, 2025. Strategically, the move makes sense. It expands the lifestyle-products operation and the medical disposable equipment activity, and tries over time to reduce dependence on tobacco.

But at this stage, it is still a beginning, not proof. The company itself says that if the transaction had been completed on January 1, 2025, consolidated revenue for the year would have been NIS 3.729 billion and consolidated net profit would have been NIS 54.7 million. In other words, even under a full-year assumption, Calir would have added roughly NIS 28.3 million of revenue and only about NIS 2.1 million of net profit. That does not undermine the strategic logic, but it does put things in perspective: Calir cannot yet offset a meaningful shock to the tobacco core.

The Pharm Express reorganization changes the 2026 read

Third trigger: in December 2025, the company reached terms with the partner in Globrands Trade and Development, exercised the option to buy the remaining stake for no consideration, and the partner bought the OTC-drug activity for NIS 1 million together with some employees, vehicles, and inventory. At the same time, the company retained the health-food, protein-bar, and pharma activities. In addition, it states that from January 1, 2026, the protein products and other consumer products previously distributed by Globrands Trade and Development will be reported under the sweets-and-snacks segment.

That point is easy to underplay, but it will matter in 2026. Segment comparisons will become less clean, because the company is not just growing, it is also moving activities between reporting layers.

The board change looks more like continuity than disruption

Fourth trigger: in January 2026, Oded Gazit was appointed as a regular director, while Yair Geller stepped down as a regular director by resignation. On its face, this is a limited governance change, not a strategic reset. But it does remind readers who controls the wheel: this is a controlled company, and both board structure and commercial relationships need to be read through that lens.

Efficiency, Profitability and Competition

The good news in 2025 is that the commercial core did not break. The less good news is that it also did not expand into a new layer that compensates for the structural risks. Gross profit increased 4.0% to NIS 237.7 million, but selling and marketing expenses rose faster, up 15.0% to NIS 104.0 million, and G&A expenses rose 6.0% to NIS 47.3 million. The result was an 11.6% decline in operating profit to NIS 85.6 million and a 23.4% decline in net profit to NIS 52.7 million.

Tobacco still carries the business

The tobacco segment remained relatively strong. Net segment sales rose to NIS 601.1 million from NIS 597.2 million in 2024, while segment result only slipped to NIS 130.6 million from NIS 133.7 million. That is a small decline, especially given that the company says tobacco sales volumes fell by 5.8%. In other words, the mechanism still works: price increases and higher excise tax still protect net revenue, and the company’s cigarette market share even rose to 37.6% from 37.4%.

That is also why the company can still look attractive on a superficial read. It holds stable market share, operates a distribution platform that is not easy to replicate, and sells into a market where brand loyalty and tolerance for price changes remain meaningful. But that resilience does not change the fact that profit still depends on two agreements, not on brands owned by the company itself.

Sweets and snacks did not deliver the next leg

The sweets-and-snacks segment fell 6.3% to NIS 90.0 million, and segment result dropped to NIS 2.9 million from NIS 5.2 million in 2024. The company attributes the decline to weaker consumption after price increases and to softer consumption in June 2025 during Operation Rising Lion. This is a segment that can look interesting on paper, because it sits on top of an existing distribution network and should theoretically benefit from the same last-mile capability. In practice, during 2025 it did not create a meaningful offset to the pressure in the core business.

The planned shift in 2026 toward mainly pre-sale distribution in sweets and snacks, instead of van-sale, may improve assortment breadth and efficiency. For now, though, it is still an operational promise that has to show up in the numbers.

Lifestyle products grew, but still did not create a new profit anchor

The lifestyle-products segment is where management’s attempt to change the mix is most visible. Net sales jumped 54.9% to NIS 93.8 million, helped by Calir’s first-time consolidation, but segment result was still close to zero at only NIS 0.1 million versus a segment loss of NIS 0.6 million in 2024. That means the company succeeded in bringing in volume, but has not yet shown that the volume translates into a meaningful new profit engine.

That is critical, because it is easy to see the growth and conclude that diversification is already working. That would be a mistake. At the segment-result level, tobacco still generates almost all of the group’s economic surplus.

What happened in the fourth quarter

A quarterly view shows that the fourth quarter was the weakest quarter of 2025. Net revenue was NIS 194.7 million, operating profit was NIS 11.1 million, and net profit was only NIS 6.8 million. That compares with operating profit of NIS 26.1 million and net profit of NIS 16.3 million in the third quarter.

The numbers suggest this was not about one isolated line. In Q4, selling and marketing expenses remained elevated, G&A stayed heavy, and the “other” line turned negative. Anyone reading only the full-year summary can miss this, but the market usually reads the tail of the year as well as the average.

Cash Flow, Debt and Capital Structure

Cash flow improved, but the all-in cash picture is still tight

This is where two frames need to be separated. Normalized cash generation improved: the company generated NIS 59.5 million of operating cash flow versus NIS 26.2 million in 2024, and EBITDA stood at NIS 105.9 million. That is not the picture of a business whose operating engine is stuck.

But all-in cash flexibility tells a tougher story. Out of NIS 59.5 million of operating cash flow, the company spent NIS 40.4 million on investing activities, mainly the Calir acquisition, vehicle renewal, and leasehold improvements; paid NIS 9.1 million of lease principal; distributed NIS 40.0 million of dividends; and also serviced a smaller amount of long-term debt. The gap was closed mainly through a NIS 33.6 million increase in short-term bank credit. That is why year-end cash rose only to NIS 12.2 million.

This is the point that needs to stay front and center. The company did not burn cash in the classic sense, but it also did not self-fund the year’s real cash uses. Anyone focusing only on the jump in operating cash flow misses that the year still relied on expanding short-term credit.

Working capital is positive, but not roomy

The company itself says the group has positive working capital. That is true. At year-end 2025 it had current assets of NIS 544.3 million against current liabilities of NIS 526.1 million. But the composition of working capital is the real issue: receivables of NIS 213.8 million, other receivables of NIS 42.3 million, and inventory of NIS 276.0 million, against payables of NIS 129.9 million and short-term bank credit of NIS 357.3 million.

The group benefits from relatively fast customer collection, with about 20 credit days across the group, but the business also sits on heavy inventory. In tobacco, that is not a technical detail. The company says explicitly that the tax paid when releasing inventory from bonded warehouses amounts to more than 87% of cigarette inventory value and more than 86% of rolling-tobacco inventory value. So even when operations run smoothly, working capital never really becomes “light.”

The cash-flow adjustments make that even clearer. In 2025, inventory released NIS 18.9 million of cash and payables added another NIS 18.3 million, but receivables rose by NIS 33.4 million and other receivables rose by NIS 17.3 million. In other words, the improvement in cash flow did not come only from a stronger operating engine. It also came from working-capital timing.

The covenants are being met, but the cushion is not wide

The company met the financial covenants with both banks, but the compliance needs to be read correctly. Tangible equity to balance sheet stood at 8.5%. That passes the December 31 test because the year-end threshold is 8%. But the March 31 and September 30 tests require 10%. In other words, the year closed above the annual floor, but below the interim benchmark. That means the company ends the year in a legal zone, not a comfortable one.

The short-term-debt-to-working-capital ratio tells a similar story: 90.6% with one bank and 90.2% with the other, against a 95% ceiling. This is not a breach, but it is also not the kind of headroom that allows investors to ignore working capital, dividends, or an operational surprise.

That said, it is important to be precise. The absolute minimum-equity covenant is not the problem right now. The company met it with tangible equity of NIS 55 million against a required minimum of NIS 16.5 million. So the real constraint is not whether equity exists, but how much pressure still sits on the ratio.

The debt structure remains exposed to rates and supplier relationships

At the end of 2025, bank credit totaled NIS 357.3 million, including NIS 341.9 million of unlinked bank loans, NIS 14.0 million under a new supplier-finance arrangement that entered in December 2025, and only negligible overdraft. Most of this exposure is floating-rate and prime-based, and the group itself notes that bank debt exposed to variable rates stood at about NIS 361 million.

That helps explain the higher finance bill. In 2025, finance expense reached NIS 18.4 million, including NIS 15.3 million of interest expense on bank loans and credit. Even if the company says, based on the Bank of Israel forecast available at the report date, that no material impact is expected, investors cannot ignore the fact that the day-to-day funding of the business is still tightly tied to prime.

On top of that, the group provides material guarantees to suppliers, especially the international tobacco companies, in the amount of about NIS 84 million. The specific guarantee stood at NIS 45 million for JTI and NIS 30 million for BAT. These are not just legal details. They are another way to see that access to the core profit engine also requires balance-sheet support.

Outlook and Forward View

Five points that matter for 2026

First finding: anyone looking at the 8.5% tangible-equity ratio and assuming the pressure has eased is missing the fact that this compliance depends on a softer year-end threshold. It is not a sign of broad headroom.

Second finding: diversification is real strategically, but not yet economically. The two non-tobacco segments together generated only about NIS 3.1 million of segment result in 2025, against NIS 130.6 million in tobacco.

Third finding: the JTI negotiation is not a distant risk. It is already part of how 2026 should be read, because the expected decline in economics affects almost half of net sales.

Fourth finding: 2026 will open with a noisier comparison base, because the changes in Globrands Trade and Development and the transfer of protein products into sweets and snacks will change the internal map.

Fifth finding: the weak fourth quarter means the company did not enter 2026 with perfect momentum. It comes into the year after a period in which the core held up, but margins and bottom-line profitability still weakened.

This looks like a bridge year, not a breakout year

At this point, 2026 looks like a bridge year. Not a reset year, because the core business is still functioning, market share is stable, and operating cash flow recovered. But it is also not a breakout year, because the company still needs to prove three things at the same time: that non-tobacco diversification becomes profitable, that the balance sheet can breathe without another round of short-term credit expansion, and that the JTI renewal does not turn 2027 into a margin-reset year.

The company itself says it does not expect to need additional funding in the coming year for ordinary operations. That is reassuring, but it needs to be read properly. It refers to ongoing operations, not to whether the company already has comfortable room for capital allocation, further deals, or external shocks.

What has to happen over the next 2 to 4 quarters

The first thing that has to happen is that the lifestyle-products segment starts contributing more at the profit level, not only at the revenue line. The company has already shown in 2025 that it can buy activity and bring in volume, but so far that volume has not materially changed the profit structure.

The second thing is that operating cash flow needs to stay strong without excessive help from working-capital timing. If inventory, receivables, and payables all move against the company while dividends or further investments continue, the cushion will narrow quickly.

The third thing is that the company needs to give the market better visibility around JTI. It may not need to close the negotiation immediately, but as long as upcoming reports come with no real clarity about the direction of terms, uncertainty will remain over the whole story.

The fourth thing is that the shift in the sweets-and-snacks distribution model and the reorganization in Globrands Trade and Development start showing real economic improvement. Without that, 2026 will remain a transition-management year rather than a year that creates a new layer of profit.

Risks

First and most important risk: deep supplier dependence. JTI and BAT together account for 75.6% of group net sales. Any commercial, structural, or regulatory change in those relationships can move quickly into the P&L. The agreements themselves allow JTI and BAT to demand dedicated distribution systems for their exclusive use. No such request has been made so far, but the fact that the right exists already shows where the bargaining power sits.

Second risk: working capital and rates. The business depends on short-term bank credit, supplier financing, heavy inventory, and guarantees. Any pressure on inventory, customer collections, rates, or dividend pace can reduce room for maneuver.

Third risk: tobacco regulation and taxation. The company already says that from August 2026 cigarette packs will have to carry graphic health warnings, and that high taxes can push customers toward cheaper brands, duty free, or the illegal market. The filing also cites an estimate that 20% to 25% of the tobacco trade in Israel is illegal. That does not mean the damage is immediate, but it does mean the company operates in a category where the regulatory direction is almost one-way.

Fourth risk: the security backdrop. As of the report date, the company said it could not estimate the possible impact of the late-February 2026 security developments on its activity and results. This is not the center of the thesis, but it is now an officially disclosed external risk.

There are also two balancing factors that matter. The first is that the company has no single customer accounting for 10% or more of revenue, so customer concentration is low. The second is that material FX exposure has fallen sharply since the main supplier agreements moved to shekel billing. In other words, the main risk is not the customer side and not FX. It is the supplier side, working capital, and commercial terms.

Conclusions

Globrands ends 2025 as a company whose business still works, but whose flexibility is still limited. The tobacco core once again proved operationally resilient, operating cash flow recovered, and management continues to build additional layers of activity. On the other hand, the picture is still not clean: short-term credit remains high, covenant headroom is not wide, and the JTI negotiation is already pulling 2027 into the 2026 story.

Current thesis: Globrands is still an efficient tobacco distributor with an active attempt to diversify the activity base, but 2025 did not change the fact that the equity case still depends mainly on whether the core can remain profitable after the next JTI agreement and on whether the company can generate real cash after all capital uses.

What has changed versus the earlier read? Two things. First, the diversification layer is a little broader now through Calir and the reorganization of the lifestyle-products platform. Second, the company now explicitly acknowledges that JTI profitability is expected to decline from 2027 if a new agreement is signed. That is a real step up in disclosure, not noise.

Strongest counter-thesis: precisely because the company keeps market share, operates with two global tobacco suppliers, passes through pricing, and gradually expands adjacent distribution activities, even some deterioration in JTI terms may prove manageable and could be absorbed through BAT, the lifestyle-products platform, and operating efficiency.

What could change the market’s interpretation over the short to medium term? Mainly three things: the pace of improvement in lifestyle-products profitability, the ongoing need for short-term credit after 2025, and any early signal about the direction of the JTI negotiation.

Why does this matter? Because this is a good example of a business where the operating moat is real, but the economic freedom available to shareholders is still not wide enough to ignore the funding layer and the power of suppliers.

What has to happen over the next 2 to 4 quarters for the thesis to strengthen? Lifestyle products need to become a meaningful profit contributor, operating cash flow needs to stay positive without more short-term credit expansion, and the company needs to offer better visibility around JTI. What would weaken the thesis? Further margin erosion, more quarters that look like Q4 2025, or signs that the newer activities are still showing up mainly in revenue rather than in profit.